QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
NASDAQ:MNKD

MannKind - MNKD Stock Forecast, Price & News

$4.04
+0.09 (+2.28%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.94
$4.09
50-Day Range
$3.95
$5.63
52-Week Range
$2.61
$5.73
Volume
2.43 million shs
Average Volume
3.27 million shs
Market Capitalization
$1.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

MannKind MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
60.9% Upside
$6.50 Price Target
Short Interest
Bearish
13.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$52,700 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.14) to $0.11 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.66 out of 5 stars

Medical Sector

833rd out of 986 stocks

Pharmaceutical Preparations Industry

400th out of 477 stocks


MNKD stock logo

About MannKind (NASDAQ:MNKD) Stock

MannKind Corp. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic products and devices for those with endocrine and orphan lung diseases. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Receive MNKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.

MNKD Stock News Headlines

MannKind Becomes Oversold (MNKD)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
MannKind Third Quarter 2022 Earnings: Beats Expectations
MannKind Q3 2022 Earnings Preview
See More Headlines
Receive MNKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.

MNKD Company Calendar

Last Earnings
2/23/2023
Today
3/23/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MNKD
CUSIP
56400P20
Employees
348
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$6.50
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+61.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-87,400,000.00
Pretax Margin
-87.60%

Debt

Sales & Book Value

Annual Sales
$99.77 million
Book Value
($0.95) per share

Miscellaneous

Free Float
257,854,000
Market Cap
$1.06 billion
Optionable
Optionable
Beta
1.68

Social Links


Key Executives

  • Michael E. CastagnaMichael E. Castagna
    Chief Executive Officer & Director
  • Steven B. BinderSteven B. Binder
    Chief Financial Officer
  • Joseph Kocinsky
    Chief Technology Officer
  • Kevin Kaiserman
    Vice President-Medical Affairs & Safety
  • Thomas Hofmann
    Chief Scientific Officer













MNKD Stock - Frequently Asked Questions

Should I buy or sell MannKind stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MNKD shares.
View MNKD analyst ratings
or view top-rated stocks.

What is MannKind's stock price forecast for 2023?

1 analysts have issued 1 year price objectives for MannKind's stock. Their MNKD share price forecasts range from $6.00 to $7.00. On average, they predict the company's share price to reach $6.50 in the next year. This suggests a possible upside of 61.7% from the stock's current price.
View analysts price targets for MNKD
or view top-rated stocks among Wall Street analysts.

How have MNKD shares performed in 2023?

MannKind's stock was trading at $5.27 at the start of the year. Since then, MNKD stock has decreased by 23.7% and is now trading at $4.02.
View the best growth stocks for 2023 here
.

When is MannKind's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our MNKD earnings forecast
.

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) issued its quarterly earnings data on Thursday, February, 23rd. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. The biopharmaceutical company had revenue of $36.06 million for the quarter, compared to analysts' expectations of $35.51 million. The firm's quarterly revenue was up 188.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.11) EPS.

What other stocks do shareholders of MannKind own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD).

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

Who are MannKind's major shareholders?

MannKind's stock is owned by many different retail and institutional investors. Top institutional shareholders include Millennium Management LLC (2.37%), Geode Capital Management LLC (1.87%), Emerald Advisers LLC (1.41%), Schonfeld Strategic Advisors LLC (1.09%), Renaissance Technologies LLC (0.74%) and Charles Schwab Investment Management Inc. (0.73%). Insiders that own company stock include Alejandro Galindo, Anthony C Hooper, David Thomson, Michael Castagna, Steven B Binder, Stuart A Tross and Stuart A Tross.
View institutional ownership trends
.

How do I buy shares of MannKind?

Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MannKind's stock price today?

One share of MNKD stock can currently be purchased for approximately $4.02.

How much money does MannKind make?

MannKind (NASDAQ:MNKD) has a market capitalization of $1.06 billion and generates $99.77 million in revenue each year. The biopharmaceutical company earns $-87,400,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

How many employees does MannKind have?

The company employs 348 workers across the globe.

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The official website for the company is www.mannkindcorp.com. The biopharmaceutical company can be reached via phone at (818) 661-5000, via email at ir@mannkindcorp.com, or via fax at 661-775-2081.

This page (NASDAQ:MNKD) was last updated on 3/23/2023 by MarketBeat.com Staff